Changing the Concepts of Immune-mediated Glomerular Diseases Through Proteomics

Overview

Journal Proteomics Clin Appl

Specialty Biochemistry

Date 2015 Apr 25

PMID 25907758

Citations 1

Authors

Dawn J Caster

Liliane Hobeika

Jon B Klein

David W Powell

Kenneth R McLeish

Affiliations

Soon will be listed here.

Abstract

Standard classification of glomerular diseases is based on histopathologic abnormalities. The recent application of proteomic technologies has resulted in paradigm changes in the understanding and classification of idiopathic membranous nephropathy and membranoproliferative glomerulonephritis. Those examples provide evidence that proteomics will lead to advances in understanding of the molecular basis of other glomerular diseases, such as lupus nephritis. Proof of principle experiments show that proteomics can be applied to patient renal biopsy specimens. This viewpoint summarizes the advances in immune-mediated glomerular diseases that have relied on proteomics, and potential future applications are discussed.

Citing Articles

FSGS Recurrence Collaboration: Report of a Symposium.

Gipson D, Wang C, Salmon E, Gbadegesin R, Naik A, Sanna-Cherchi S Glomerular Dis. 2024; 4(1):1-10.

PMID: 38348154 PMC: 10859699. DOI: 10.1159/000535138.

References

Kanigicherla D, Gummadova J, Mckenzie E, Roberts S, Harris S, Nikam M . Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int. 2013; 83(5):940-8. DOI: 10.1038/ki.2012.486. View

Nowling T, Gilkeson G . Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther. 2011; 13(6):250. PMC: 3334648. DOI: 10.1186/ar3528. View

Hofstra J, Fervenza F, Wetzels J . Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol. 2013; 9(8):443-58. DOI: 10.1038/nrneph.2013.125. View

Lv J, Hou W, Zhou X, Liu G, Zhou F, Zhao N . Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy. J Am Soc Nephrol. 2013; 24(8):1323-9. PMC: 3736719. DOI: 10.1681/ASN.2012080771. View

Seredkina N, van der Vlag J, Berden J, Mortensen E, Rekvig O . Lupus nephritis: enigmas, conflicting models and an emerging concept. Mol Med. 2013; 19:161-9. PMC: 3745592. DOI: 10.2119/molmed.2013.00010. View

Satoskar A, Shapiro J, Bott C, Song H, Nadasdy G, Brodsky S . Characterization of glomerular diseases using proteomic analysis of laser capture microdissected glomeruli. Mod Pathol. 2012; 25(5):709-21. PMC: 3432020. DOI: 10.1038/modpathol.2011.205. View

Fenton K, Tommeras B, Marion T, Rekvig O . Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity. 2009; 43(2):179-88. DOI: 10.3109/08916930903305633. View

Prunotto M, Carnevali M, Candiano G, Murtas C, Bruschi M, Corradini E . Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol. 2010; 21(3):507-19. PMC: 2831859. DOI: 10.1681/ASN.2008121259. View

Yung S, Cheung K, Zhang Q, Chan T . Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol. 2010; 21(11):1912-27. PMC: 3014006. DOI: 10.1681/ASN.2009080805. View

10.

Sethi S, Theis J, Leung N, Dispenzieri A, Nasr S, Fidler M . Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol. 2010; 5(12):2180-7. PMC: 2994078. DOI: 10.2215/CJN.02890310. View

11.

Stanescu H, Arcos-Burgos M, Medlar A, Bockenhauer D, Kottgen A, Dragomirescu L . Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med. 2011; 364(7):616-26. DOI: 10.1056/NEJMoa1009742. View

12.

Qin W, Beck Jr L, Zeng C, Chen Z, Li S, Zuo K . Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol. 2011; 22(6):1137-43. PMC: 3103733. DOI: 10.1681/ASN.2010090967. View

13.

Bruschi M, Sinico R, Moroni G, Pratesi F, Migliorini P, Galetti M . Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI. J Am Soc Nephrol. 2014; 25(11):2483-98. PMC: 4214525. DOI: 10.1681/ASN.2013090987. View

14.

Tomas N, Beck Jr L, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G . Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014; 371(24):2277-2287. PMC: 4278759. DOI: 10.1056/NEJMoa1409354. View

15.

Murtas C, Bruschi M, Candiano G, Moroni G, Magistroni R, Magnano A . Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol. 2012; 7(9):1394-400. PMC: 3430946. DOI: 10.2215/CJN.02170312. View

16.

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

17.

Fresquet M, Jowitt T, Gummadova J, Collins R, Ocualain R, Mckenzie E . Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy. J Am Soc Nephrol. 2014; 26(2):302-13. PMC: 4310666. DOI: 10.1681/ASN.2014050502. View

18.

Sethi S, Fervenza F, Zhang Y, Zand L, Vrana J, Nasr S . C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012; 82(4):465-73. PMC: 4438675. DOI: 10.1038/ki.2012.212. View

19.

Bomback A, Appel G . Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012; 8(11):634-42. DOI: 10.1038/nrneph.2012.213. View

20.

Olson S, Lee J, Prince L, Baker T, Papadopoulos P, Edison J . Elevated subclinical double-stranded DNA antibodies and future proliferative lupus nephritis. Clin J Am Soc Nephrol. 2013; 8(10):1702-8. PMC: 3789337. DOI: 10.2215/CJN.01910213. View